Funding Opportunities of Note
- NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1)
- Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2)
- Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01)
- HIV/AIDS High Priority Drug Abuse Research (R01)
- Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33)
- Implementing the HIV Service Cascade for Justice-Involved Populations (U01)
- Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33)
- Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34)
Program Announcements
- Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required) PAR-21-039
- Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) PAR-21-038
- New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required) PAR-20-273
- New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional ) PAR-20-274
- Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed) PA-20-151
- HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed) PA-20-149
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) PAR-20-147
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) PAR-20-148
- Centers for AIDS Research (P30 Clinical Trial Not Allowed) PAR-20-106
- Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) PAR-20-107
- Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) PAR-20-036
- Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional) PAR-19-283
- Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed) PAR-19-285
- Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed) PAR-19-284
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PA-18-916
Request for Applications
- Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed) RFA-DA-22-002
- Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional) RFA-AI-21-024
- Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional) RFA-AI-21-025
- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional) RFA-AI-21-023
- Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional) RFA-DA-21-005
Notices of Special Interest (NOSI)
- Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity NOT-DA-21-014 - R01,R21,DP2,DP1,K99/R00,K01,R36,P01,R15,K24
- Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning NOT-DA-21-007 - R01,R21
- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes NOT-DA-20-018 - R01,R03,R21,333
- Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches NOT-DA-20-032 - R01
Notices
- Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-001, "Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)" NOT-DA-21-009
- Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-002, "Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)" NOT-DA-21-010
- Notice of Correction to PAR-20-221, "NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)" NOT-DA-20-066
- Notice of Intent to Publish a Funding Opportunity Announcement for Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) NOT-DA-20-045
- Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) NOT-DA-20-044
- Notice of NIDA Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)" NOT-DA-20-016
- Notice of Intent to Publish a Funding Opportunity Announcement for Implementing the HIV Service Cascade for Justice-Involved Populations NOT-DA-20-003
- Notice of Changes to RFA-AI-19-002 "HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (UM1 Clinical Trial Required)" NOT-AI-19-051